التجارب السريرية بالأسفل التجارب السريرية الحالية.38 دراسات في برنامج سرطان الرئة (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. A Dose Escalation Study of Amivantamab in Participants with Advanced Non-Small Cell Lung Cancer Rochester, Minn. The purpose of this study is to evaluate the safety and pharmacokinetics, establish a recommended phase 2 dose (RP2D) regimen, and to assess the preliminary effectiveness of JNJ-61186372 in participants with advanced non-small cell lung cancer (NSCLC). A Study to Evaluate Immunotherapy for Non-Small Cell Lung Cancer Scottsdale/Phoenix, Ariz. The primary objectives of this study are to evaluate safety/tolerability and immunogenicity of IMU-201 as monotherapy and in combination with an immune checkpoint inhibitor (ICI) or an ICI and chemotherapy in participants with advanced NSCLC tumors that are positive for PD-L1, and to identify the Optimal Biological Dose (OBD) of IMU-201 as monotherapy and in combination with an ICI, or an ICI and chemotherapy, in participants with advanced NSCLC tumors that are positive for PD-L1. A Study to Evaluate a Health and Wellness Coaching Model in Support of Caregivers of Patients with Advanced Lung Cancers Jacksonville, Fla. Piloting the BeWell360-CG model, in conjunction with usual care delivery for lung cancer patients in Palliative Care, will longitudinally improve the wellbeing and quality of life of care givers within and outside of clinical care settings, in such a way as to positively impact the quality of care of patients themselves. We hypothesize that PC staff trained in the BeWell360-CG will be able to identify the most common CG-centric needs and guide CGs to improve their QoL and personal wellbeing. In doing so, we further hypothesize that there will be an improvement in patient-reported and quality of care outcomes. The objective of this proposal is to pilot a novel, scalable, user-friendly HWC care model– the BeWell360-CG— that is embedded and integrated as part of a palliative approach to care for CGs of patients with advanced lung cancer. A Study to Evaluate Exemestane in Post-Menopausal Women with Non-Small Cell Lung Cancer (NSCLC) Albert Lea, Minn., Mankato, Minn. This study is being conducted to see if adding Exemestane to the immune checkpoint blockade can slow disease progression in post-menopausal women with non-small cell lung cancer. A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Scottsdale/Phoenix, Ariz. This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®). A Study to Evaluate Fractionated Radiation Therapy Utilizing GRID Therapy for Locally-advanced Bulky Tumors Rochester, Minn., Jacksonville, Fla. The purpose of this research is to study radiographic control at the 3 month time-point, the side effects (good & bad), survival outcomes and proof of this idea in patients who have had grid therapy for locally advanced bulky tumors of the heat and neck, thorax, abdomen and extremities. A Study To Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the effect of canakinumab or pembrolizumab as monotherapy or combined as neo-adjuvant treatment for subjects with early stage non-small cell lung cancer. A Study to Evaluate Whether Probiotics for Gut Microbiome Will Target Cancer Immune Microenvironment in Breast and Lung Cancer Jacksonville, Fla. The purpose of this study is to evaluate whether engineering gut microbiome using probiotics will alter host immunological response to breast and lung cancers. Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients with Advanced Solid Tumors Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to demonstrate the safety and tolerability of JAB-3312 in combination with anti-PD-1 mAb or MEKi or KRASi or EGFR-TKI in patients with advanced solid tumors. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and CNS metastases of non-small cell lung cancer (NSCLC). التصفّح دراسات سريرية توجّه للصفحة 11 توجّه للصفحة 22 توجّه للصفحة 33 توجّه للصفحة 44 التاليالصفحة التالية طلب موعد في مايو كلينيك الأخبار من Mayo Clinicالأبحاث 11/02/2022 تبادلها عبر ارسلها على الفيس بوكارسلها في تغريدة بالأسفل التجارب السريرية الحالية.38 دراسات في برنامج سرطان الرئة (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. A Study to Evaluate Immunotherapy for Non-Small Cell Lung Cancer Scottsdale/Phoenix, Ariz. The primary objectives of this study are to evaluate safety/tolerability and immunogenicity of IMU-201 as monotherapy and in combination with an immune checkpoint inhibitor (ICI) or an ICI and chemotherapy in participants with advanced NSCLC tumors that are positive for PD-L1, and to identify the Optimal Biological Dose (OBD) of IMU-201 as monotherapy and in combination with an ICI, or an ICI and chemotherapy, in participants with advanced NSCLC tumors that are positive for PD-L1. A Study to Evaluate a Health and Wellness Coaching Model in Support of Caregivers of Patients with Advanced Lung Cancers Jacksonville, Fla. Piloting the BeWell360-CG model, in conjunction with usual care delivery for lung cancer patients in Palliative Care, will longitudinally improve the wellbeing and quality of life of care givers within and outside of clinical care settings, in such a way as to positively impact the quality of care of patients themselves. We hypothesize that PC staff trained in the BeWell360-CG will be able to identify the most common CG-centric needs and guide CGs to improve their QoL and personal wellbeing. In doing so, we further hypothesize that there will be an improvement in patient-reported and quality of care outcomes. The objective of this proposal is to pilot a novel, scalable, user-friendly HWC care model– the BeWell360-CG— that is embedded and integrated as part of a palliative approach to care for CGs of patients with advanced lung cancer. A Study to Evaluate Exemestane in Post-Menopausal Women with Non-Small Cell Lung Cancer (NSCLC) Albert Lea, Minn., Mankato, Minn. This study is being conducted to see if adding Exemestane to the immune checkpoint blockade can slow disease progression in post-menopausal women with non-small cell lung cancer. A Dose Escalation Study of Amivantamab in Participants with Advanced Non-Small Cell Lung Cancer Rochester, Minn. The purpose of this study is to evaluate the safety and pharmacokinetics, establish a recommended phase 2 dose (RP2D) regimen, and to assess the preliminary effectiveness of JNJ-61186372 in participants with advanced non-small cell lung cancer (NSCLC). A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Scottsdale/Phoenix, Ariz. This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®). A Study to Evaluate Fractionated Radiation Therapy Utilizing GRID Therapy for Locally-advanced Bulky Tumors Rochester, Minn., Jacksonville, Fla. The purpose of this research is to study radiographic control at the 3 month time-point, the side effects (good & bad), survival outcomes and proof of this idea in patients who have had grid therapy for locally advanced bulky tumors of the heat and neck, thorax, abdomen and extremities. A Study To Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the effect of canakinumab or pembrolizumab as monotherapy or combined as neo-adjuvant treatment for subjects with early stage non-small cell lung cancer. A Study to Evaluate Whether Probiotics for Gut Microbiome Will Target Cancer Immune Microenvironment in Breast and Lung Cancer Jacksonville, Fla. The purpose of this study is to evaluate whether engineering gut microbiome using probiotics will alter host immunological response to breast and lung cancers. Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients with Advanced Solid Tumors Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to demonstrate the safety and tolerability of JAB-3312 in combination with anti-PD-1 mAb or MEKi or KRASi or EGFR-TKI in patients with advanced solid tumors. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and CNS metastases of non-small cell lung cancer (NSCLC). التصفّح دراسات سريرية توجّه للصفحة 11 توجّه للصفحة 22 توجّه للصفحة 33 توجّه للصفحة 44 التاليالصفحة التالية برنامج سرطان الرئةالصفحة الرئيسية للقسمالأجزاءنظرة عامةالاختبارات والتشخيصالحلات التي يتم علاجهاالأطباءالأطباء حسب الموقع والتخصُّصمجموعات التخصصالخبرة و مراتب التصنيفالمواقع والسفر والإقامةالتكاليف والتأمين الصحيالأخبار من Mayo Clinicالتجارب السريريةالأبحاثإحالة المرضى الأبحاث: الأمر برمته يتوقف على المرضى الأجزاءطلب موعدنظرة عامةالاختبارات والتشخيصالحلات التي يتم علاجهاالأطباءالأطباء حسب الموقع والتخصُّصمجموعات التخصصالخبرة و مراتب التصنيفالمواقع والسفر والإقامةالتكاليف والتأمين الصحيالأخبار من Mayo Clinicالتجارب السريريةالأبحاثإحالة المرضى ORG-20461564 الأقسام والمراكز المراكز والأقسام الطبية برنامج سرطان الرئة